Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Immunicum AB (publ) Announces the Outcome of the Rights Issue

Immunicum AB
Posted on: 29 Dec 17

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED OR RELEASED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, CANADA OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES THAN THOSE REQUIRED BY SWEDISH LAW.

Press Release

29 December 2017

Immunicum AB (publ) Announces the Outcome of the Rights Issue

Immunicum AB (publ) (First North Premier: IMMU.ST), ("Immunicum" or "the Company"), a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that the 90 percent secured Rights Issue with preferential rights for existing shareholders which was announced on 2 November 2017 (the "Rights Issue") has been completed. Immunicum's proceeds from the Rights Issue amount to approximately SEK 200 million before transaction costs.

A total of approximately SEK 100 million, corresponding to 44.9 percent of the Rights Issue was subscribed for. Approximately SEK 95 million, corresponding to 42.6 percent of the Rights Issue, was subscribed for by way of subscription rights and approximately SEK 5 million, corresponding to 2.3 percent of the Rights Issue, was subscribed for and allotted to investors who have subscribed for shares without subscription rights. The remaining share of the secured part of the Rights Issue, corresponding to approximately SEK 100 million, was allotted to guarantors.

Shares subscribed for without subscription rights have been allotted in accordance with the principles stated in the prospectus prepared in connection with the Rights Issue and published on 5 December 2017. Notice of the allotment of shares subscribed for without subscription rights will be sent shortly to those who have been allotted shares. Payment for the subscribed and allotted new shares is to be made in cash and the payment must be received by Pareto Securities AB not later than on the settlement day, on or about 4 January 2018, in accordance with the instructions on the contract note.

In total, the Rights Issue provides Immunicum with approximately SEK 168 million after deduction of transaction costs. The number of shares will increase from 25,958,541 to 50,958,531 shares when the new shares have been registered with the Swedish Companies Registration Office. When such registration has been made, paid subscribed shares ( Sw. betalda tecknade aktier) will be converted into common shares. The preliminary record date for such conversion is 11 January 2018, whereby the paid subscribed shares will be converted into new shares on or about 15 January 2018. Trading in the new shares on Nasdaq Stockholm is expected to start on the same day.

"The completion of the Rights Issue will enable us to conclude the Phase II MERECA and the Phase I/II GIST clinical trials for ilixadencel and to achieve a first decision point in the planned multi-indication study with ilixadencel in combination with checkpoint inhibitors, all important value inflection milestones for the company. In addition, we have secured more than sufficient working capital for the coming twelve months, which means we have fulfilled that requirement for the listing of Immunicum's shares on Nasdaq Stockholm," stated Carlos de Sousa, CEO of Immunicum. "We appreciate the support from our shareholders and their confidence in ilixadencel's potential as an exciting therapy for patients suffering from a broad range of solid tumors."

Advisors

Pareto Securities AB is acting as financial advisor and Advokatfirman Delphi is legal advisor to Pareto Securities AB and Immunicum in connection with the Rights Issue.

The information is such information that Immunicum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 29 December 2017 at 12.00 pm CET.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: +46 709 71 12 53
E-mail: ir@immunicum.com

Investor and Media Relations EU/US

Gretchen Schweitzer
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Immunicum AB via GlobeNewswire
HUG#2158711
GlobeNewswire
globenewswire.com

Last updated on: 30/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.